AEYE is up +392.76% since Feb ’24 pick Unlock All Top Buy Picks

BRIEF-Cormedix Q4 Loss Per Share $0.21

10:41pm, Monday, 16'th Mar 2020
* . REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Company in process of submitting New Drug Application (NDA) for Neutrolin® for prevention of catheter-related blood stream infections via a rolling review granted by FDA.

CorMedix, Inc. to Host Earnings Call

06:30pm, Monday, 16'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 16, 2020 / CorMedix, Inc. (AMEX:CRMD) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at 4:30 PM Eas
Aimmune to rise sharply on DBV Technologies setback, says Piper Sandler Piper Sandler AIMT DBVT
Arthur J. Gallagher upgraded to Outperform from Market Perform at Keefe Bruyette Keefe Bruyette AJG AON WLTW
Petrofac upgraded to Buy from Neutral at Goldman Sachs Goldman Sachs POFCY
Subsea 7 upgraded to Buy from Neutral at Goldman Sachs Goldman Sachs SUBCY
PGS ASA downgraded to Sell from Buy at Goldman Sachs Goldman Sachs PGSVY
Vallourec downgraded to Neutral from Buy at Goldman Sachs Goldman Sachs VLOUF
ExxonMobil weighs steps to significantly cut capital, Bloomberg reports XOM
Eldorado Resorts temporarily suspends operations at Tropicana Atlantic City ERI
Fly Intel: After Hours Movers COUP TME TMO AVEO HQY CRMD DBVT CLB STXS
Abbott's Boudreau sells over 10,000 common shares ABT
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE